AC Immune SA (NASDAQ:ACIU)

3.16
Delayed Data
As of May 20
 +0.04 / +1.28%
Today’s Change
2.46
Today|||52-Week Range
12.61
-36.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$263.0M

Company Description

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Contact Information

AC Immune SA
EPFL Innovation Park
Lausanne Vaud 1015
P:(121) 345-9121
Investor Relations:
(121) 345-9191

Employees

Shareholders

Mutual fund holders6.16%
Other institutional14.78%
Individual stakeholders--

Top Executives

Andrea PfeiferChief Executive Officer & Director
Jörg HornsteinChief Financial Officer
Oliver SolVP & Head-Clinical Development
Piergiorgio DonatiChief Technical Operations Officer
Marie Kosco-VilboisChief Scientific Officer